Sees FY25 gross margin 54%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes sees Q1 revenue $219M-$224M, consensus $248.4M1
- Tandem Diabetes reports Q4 EPS 1c, consensus (24c)
- Tandem Diabetes Care: Positioned for Growth with FDA Approval of Control IQ+
- FDA clears Tandem’s Control-IQ+ for type 2 diabetes treatment
- TNDM Upcoming Earnings Report: What to Expect?